Headline
The latest stories from AHA Today.
The AHA and Federation of American Hospitals Aug. 8 filed an amicus brief in the U.S. District Court for the Eastern District of Texas in support of the U.S. Chamber of Commerce’s lawsuit against the Federal Trade Commission, explaining that changes made by the FTC to premerger notification rules…
The National Institutes of Health Aug. 5 issued guidance to researchers on the use of artificial intelligence for the research application process.
The U.S. Departments of Labor, Health and Human Services, and the Treasury announced Aug. 7 that they are reconsidering the definition of short-term, limited-duration insurance through a formal rulemaking process.
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the timeline for stakeholder comments, agency consideration and manufacturer rebate plan submissions for its 340B Rebate Model Pilot Program.
The Centers for Disease Control and Prevention and the Department of Health and Human Services adopted Aug. 4 the Advisory Committee on Immunization Practices’ recommendations for respiratory syncytial virus and seasonal influenza vaccinations ahead of the 2025-2026 respiratory infection season.
President Trump Aug. 7 issued an executive order, “Improving Oversight of Federal Grantmaking,” requiring government agencies to review new and discretionary grants to ensure grant funding advances the administration’s policy priorities.
The AHA has elected nine new members to its Board of Trustees for three-year terms beginning Jan. 1.
The AHA Aug. 7 launched a new webpage, Reducing Disparities in Health Outcomes, featuring new and familiar resources for members and their communities.
The AHA Aug. 7 filed an amicus brief in the Supreme Court in defense of states’ affidavit of merit requirements in federal court, which require plaintiffs to file a report from a health care provider affirming that a medical malpractice claim has merit before the case can proceed.
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by increasing regulatory predictability and facilitating the construction of drug manufacturing facilities in the U.S.